Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer
NCT ID: NCT00888511
Last Updated: 2020-11-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
15 participants
INTERVENTIONAL
2009-05-31
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Tarceva
Tarceva 150 mg/day
Radiotherapy
66 Gy/33 F/5 F per week for 5 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tarceva
Tarceva 150 mg/day
Radiotherapy
66 Gy/33 F/5 F per week for 5 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with histologically or cytologically documented diagnosis locally advanced NSCLC stage IIB to IIIB without pleural effusion
* Performance status ≤2 on the ECOG scale
* Serum bilirubin must be ≤1.5 upper limit of normal (ULN)
* ALAT ≤2 x ULN
* Able to comply with study and follow-up procedures
* Patients with reproductive potential must use effective contraception
* Written (signed) informed consent to participate in the study
Exclusion Criteria
* Any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)
* Inability to take oral medication, or requirement of intravenous alimentation
* Nursing mothers
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Odense University Hospital
OTHER
Copenhagen University Hospital at Herlev
OTHER
Rigshospitalet, Denmark
OTHER
Aalborg University Hospital
OTHER
Aarhus University Hospital
OTHER
Naestved Hospital
OTHER
Olfred Hansen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Olfred Hansen
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olfred Hansen, MD
Role: PRINCIPAL_INVESTIGATOR
Odense University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Oncology, Aarhus University Hospital
Aarhus, , Denmark
Department of Oncology, Rigshospitalet
Copenhagen, , Denmark
Department of Oncology, Copenhagen University Hospital at Herlev
Herlev, , Denmark
Department of Oncology, Naestved Hospital
Næstved, , Denmark
Laboratory of Radiation Physics
Odense, , Denmark
Odense University Hospital
Odense, , Denmark
Department of Oncology, Vejle Hospital
Vejle, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09.02
Identifier Type: -
Identifier Source: org_study_id